Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
98 hedge funds and large institutions have $167M invested in Five Prime Therapeutics, Inc. in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 10 closing their positions.
188% more capital invested
Capital invested by funds: $57.9M → $167M (+$109M)
165% more call options, than puts
Call options by funds: $567K | Put options by funds: $214K
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
13% more funds holding
Funds holding: 87 → 98 (+11)
9% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 33
Top Buyers
Top Sellers
| 1 |
BlackRock
New York
|
-$1.49M |
| 2 |
Renaissance Technologies
New York
|
-$939K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$568K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$545K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$433K |
FPRX Hedge Fund Activity: Q2 2020 in Review
98 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2020, worth a combined $167M — up 188% from $57.9M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FPRX positions and 10 closed out — a net gain of 12 holders — while 30 added to existing stakes and 33 trimmed.
The largest buyer was Candriam SCA, adding an estimated $2.07M. The largest seller was BlackRock, cutting an estimated $1.49M.
- 98 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2020, up from 87 in Q1 2020.
- Funds reported $167M of Five Prime Therapeutics, Inc. stock for Q2 2020, up 188% quarter-over-quarter.
- 22 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2020 and 10 closed out, a net change of +12 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q2 2020 was Candriam SCA, an estimated $2.07M added.
- The largest Five Prime Therapeutics, Inc. seller in Q2 2020 was BlackRock, an estimated $1.49M sold.
Based on aggregated 13F filings for Q2 2020.